Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi'an Jiaotong University, Xi'an, China; Center for Drug Safety and Policy Research, Xi'an Jiaotong University, Xi'an, China; Institute for Global Health and Development, Peking University, Beijing, China.
Department of Health Policy and Management, School of Public Health, Peking University, Beijing, China; China Center for Health Development Studies, Peking University, Beijing, China; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA; International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA.
Vaccine. 2024 Nov 14;42(25):126150. doi: 10.1016/j.vaccine.2024.07.051. Epub 2024 Aug 1.
In late 2022, China became the first country to roll out mucosal COVID-19 vaccines. No prior study has yet compared the immunization stress-related responses (ISRR) among different routes of COVID-19 vaccine delivery. We aimed to compare the immunization-related psychological stress and ISRR between mucosal and intramuscular COVID-19 vaccines.
A cross-sectional questionnaire survey using a biopsychosocial framework design was performed from January 11 to 20, 2023. Adults with COVID-19 vaccination were eligible for the study, and a total of 1073 adults participated with community-based sample. Primary outcomes were the psychological stress levels and prevalence of ISRR. Multivariate regression models were employed to compare these outcomes between the two vaccination groups. The potential mediating effects of stress on vaccination and ISRR were examined using bootstrap sampling method. To further ensure the robustness of our results, sensitivity analysis with propensity score matching was performed.
In the univariate analysis, participants who received mucosal vaccination reported significantly lower stress levels compared to those who received intramuscular vaccination (3.39 ± 3.02 vs. 3.93 ± 3.24, P = .006). The prevalence of overall ISRR was significantly lower in the mucosal group compared to the intramuscular group (38.4% vs. 47.9%, P = .002). Multivariate regression models revealed that participants who received mucosal vaccination had a significantly lower stress level (β = -0.516, 95% CI: -0.852 to -0.180; P = .003) and 38.7% fewer overall ISRR (OR = 0.613, 95% CI: 0.427 to 0.881; P = .008), particularly in terms of neurological symptoms. The immunization-related stress mediated the association between vaccination type and ISRR, with indirect effects estimated at 0.0663 (95% CI: 0.0195 to 0.1346) for overall ISRR.
Mucosal COVID-19 vaccination was associated with reduced psychological stress and physical responses, as compared to intramuscular vaccination, which may contribute to increased trust and compliance with routine or mass vaccination efforts in the future.
2022 年末,中国成为首个推出黏膜 COVID-19 疫苗的国家。此前尚无研究比较不同 COVID-19 疫苗接种途径的免疫应激相关反应(ISRR)。本研究旨在比较黏膜和肌肉内 COVID-19 疫苗接种的免疫相关心理应激和 ISRR。
2023 年 1 月 11 日至 20 日,采用生物心理社会框架设计进行了一项横断面问卷调查。有 COVID-19 疫苗接种史的成年人符合研究条件,共有 1073 名成年人参与了社区为基础的抽样。主要结局为心理应激水平和 ISRR 发生率。采用多元回归模型比较两组的这些结局。采用自举抽样法检验应激对疫苗接种和 ISRR 的潜在中介作用。为了进一步确保结果的稳健性,进行了倾向评分匹配的敏感性分析。
在单变量分析中,与接受肌肉内接种的参与者相比,接受黏膜接种的参与者报告的应激水平显著更低(3.39±3.02 与 3.93±3.24,P=.006)。黏膜组的总 ISRR 发生率显著低于肌肉内组(38.4%与 47.9%,P=.002)。多元回归模型显示,接受黏膜接种的参与者应激水平显著更低(β=-0.516,95%CI:-0.852 至-0.180;P=.003),总 ISRR 减少 38.7%(OR=0.613,95%CI:0.427 至 0.881;P=.008),尤其是在神经系统症状方面。免疫相关应激中介了接种类型与 ISRR 之间的关联,总 ISRR 的间接效应估计值为 0.0663(95%CI:0.0195 至 0.1346)。
与肌肉内接种相比,黏膜 COVID-19 疫苗接种与心理应激和身体反应减少相关,这可能有助于提高未来对常规或大规模疫苗接种工作的信任和依从性。